Chicago Partners Investment Group LLC Buys Shares of 10,756 Royalty Pharma PLC $RPRX

Chicago Partners Investment Group LLC acquired a new position in Royalty Pharma PLC (NASDAQ:RPRX) during the 1st quarter, Holdings Channel reports. The firm acquired 10,756 shares of the biopharmaceutical company’s stock, valued at approximately $535,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. LM Advisors LLC purchased a new position in Royalty Pharma during the fourth quarter valued at $26,000. Lloyd Advisory Services LLC. bought a new stake in shares of Royalty Pharma during the 4th quarter valued at $30,000. Private Trust Co. NA raised its position in shares of Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 288 shares during the period. Blue Trust Inc. lifted its stake in shares of Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 437 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its stake in shares of Royalty Pharma by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 446 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Down 0.6%

RPRX opened at $58.18 on Friday. The stock has a market cap of $33.50 billion, a price-to-earnings ratio of 39.58, a P/E/G ratio of 10.30 and a beta of 0.43. The stock’s 50 day moving average price is $55.01 and its 200-day moving average price is $48.52. Royalty Pharma PLC has a one year low of $34.08 and a one year high of $59.44. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The firm had revenue of $630.58 million during the quarter, compared to analyst estimates of $881.69 million. On average, equities analysts forecast that Royalty Pharma PLC will post 5.18 EPS for the current year.

Analyst Upgrades and Downgrades

RPRX has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Morgan Stanley lifted their price objective on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Citigroup upped their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, UBS Group upped their price objective on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $56.57.

Insiders Place Their Bets

In other news, CFO Terrance P. Coyne sold 64,399 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $53.98, for a total transaction of $3,476,258.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $56.52, for a total transaction of $5,652,000.00. Following the completion of the transaction, the executive vice president owned 459,399 shares in the company, valued at approximately $25,965,231.48. The trade was a 17.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 427,800 shares of company stock worth $23,333,723. 18.84% of the stock is currently owned by company insiders.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.